CN102372766B - 一种o型口蹄疫多表位疫苗 - Google Patents
一种o型口蹄疫多表位疫苗 Download PDFInfo
- Publication number
- CN102372766B CN102372766B CN 201110195278 CN201110195278A CN102372766B CN 102372766 B CN102372766 B CN 102372766B CN 201110195278 CN201110195278 CN 201110195278 CN 201110195278 A CN201110195278 A CN 201110195278A CN 102372766 B CN102372766 B CN 102372766B
- Authority
- CN
- China
- Prior art keywords
- gca
- ggt
- vaccine
- gtt
- cgt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 164
- 241000710198 Foot-and-mouth disease virus Species 0.000 title claims abstract description 90
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 title claims description 73
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 241000282326 Felis catus Species 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 abstract description 39
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 38
- 230000036039 immunity Effects 0.000 abstract description 34
- 229920001184 polypeptide Polymers 0.000 abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 9
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000000890 antigenic effect Effects 0.000 abstract description 4
- 101710116435 Outer membrane protein Proteins 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 55
- 238000012360 testing method Methods 0.000 description 50
- 239000000427 antigen Substances 0.000 description 37
- 102000036639 antigens Human genes 0.000 description 36
- 108091007433 antigens Proteins 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 33
- 239000002574 poison Substances 0.000 description 27
- 231100000614 poison Toxicity 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 23
- 101710132601 Capsid protein Proteins 0.000 description 21
- 101710197658 Capsid protein VP1 Proteins 0.000 description 21
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 21
- 101710108545 Viral protein 1 Proteins 0.000 description 21
- 241000700605 Viruses Species 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 210000003719 b-lymphocyte Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 230000036541 health Effects 0.000 description 15
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 241000282887 Suidae Species 0.000 description 12
- 230000036528 appetite Effects 0.000 description 12
- 235000019789 appetite Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 11
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 11
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 11
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 11
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 11
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 101710081079 Minor spike protein H Proteins 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000010171 animal model Methods 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000012827 research and development Methods 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000009849 deactivation Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000001524 infective effect Effects 0.000 description 7
- 244000144972 livestock Species 0.000 description 7
- 235000013372 meat Nutrition 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 229940031551 inactivated vaccine Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000009781 safety test method Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 231100000041 toxicology testing Toxicity 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 108010042653 IgA receptor Proteins 0.000 description 5
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000004153 renaturation Methods 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229940023041 peptide vaccine Drugs 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000005498 polishing Methods 0.000 description 4
- 229940124551 recombinant vaccine Drugs 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- 231100000645 Reed–Muench method Toxicity 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000030194 mouth disease Diseases 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 208000011309 nasal bleeding Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710203389 Outer membrane porin F Proteins 0.000 description 2
- 101710160102 Outer membrane protein B Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 1
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical class [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- -1 mono-O Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
组别 | 动物数量 | 精神 | 活动 | 食欲 | 健康状况 | 死亡数量 |
20090603 | 5 | 正常 | 正常 | 正常 | 健康状况良好 | 0 |
20090605 | 5 | 正常 | 正常 | 正常 | 健康状况良好 | 0 |
20090608 | 5 | 正常 | 正常 | 正常 | 健康状况良好 | 0 |
对照组 | 2 | 正常 | 正常 | 正常 | 健康状况良好 | 0 |
组别 | 动物数量 | 精神 | 活动 | 食欲 | 健康状况 | 死亡数量 |
20090603 | 5 | 正常 | 正常 | 正常 | 健康状况良好 | 0 |
20090605 | 5 | 正常 | 正常 | 正常 | 健康状况良好 | 0 |
20090608 | 5 | 正常 | 正常 | 正常 | 健康状况良好 | 0 |
对照组 | 2 | 正常 | 正常 | 正常 | 健康状况良好 | 0 |
组别 | 动物数量 | 体温 | 食欲 | 异常状况 | 死亡数量 |
20090603 | 5 | 正常 | 正常 | 无 | 0 |
20090605 | 5 | 正常 | 正常 | 无 | 0 |
20090608 | 5 | 正常 | 正常 | 无 | 0 |
对照组 | 2 | 正常 | 正常 | 无 | 0 |
组别 | 动物数量 | 体温 | 食欲 | 异常状况 | 死亡数量 |
20090603 | 5 | 正常 | 正常 | 无 | 0 |
20090605 | 5 | 正常 | 正常 | 无 | 0 |
20090608 | 5 | 正常 | 正常 | 无 | 0 |
对照组 | 2 | 正常 | 正常 | 无 | 0 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110195278 CN102372766B (zh) | 2011-07-13 | 2011-07-13 | 一种o型口蹄疫多表位疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110195278 CN102372766B (zh) | 2011-07-13 | 2011-07-13 | 一种o型口蹄疫多表位疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102372766A CN102372766A (zh) | 2012-03-14 |
CN102372766B true CN102372766B (zh) | 2013-12-25 |
Family
ID=45792038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110195278 Active CN102372766B (zh) | 2011-07-13 | 2011-07-13 | 一种o型口蹄疫多表位疫苗 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102372766B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892734B (zh) * | 2015-04-30 | 2019-09-13 | 中国科学院过程工程研究所 | 疏水作用层析提纯口蹄疫灭活病毒抗原的方法 |
CN107827986B (zh) * | 2017-05-09 | 2019-09-24 | 青岛明勤生物科技有限公司 | 猪O/Mya98和O/PanAsia型口蹄疫基因工程灭活疫苗 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1711025A (zh) * | 2002-10-03 | 2005-12-21 | 艾普免疫公司 | 优化的多表位构建体及其应用 |
CN101948811A (zh) * | 2010-08-18 | 2011-01-19 | 中国农业科学院兰州兽医研究所 | 用反向遗传操作拓展口蹄疫疫苗株抗原谱及疫苗制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1290579C (zh) * | 2003-10-15 | 2006-12-20 | 北京迪威华宇生物技术有限公司 | 重组口蹄疫病毒vp1融合蛋白疫苗 |
CN1737144A (zh) * | 2004-08-18 | 2006-02-22 | 金宁一 | 口蹄疫复合多表位二价核酸疫苗的构建 |
CN100582122C (zh) * | 2006-05-12 | 2010-01-20 | 北京宝麦德生物医药科技有限责任公司 | O型口蹄疫病毒多表位粘膜免疫疫苗及其应用 |
CN101293098A (zh) * | 2007-04-28 | 2008-10-29 | 北京迪威华宇生物技术有限公司 | 一种重组牛o型口蹄疫病毒融合蛋白疫苗 |
-
2011
- 2011-07-13 CN CN 201110195278 patent/CN102372766B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1711025A (zh) * | 2002-10-03 | 2005-12-21 | 艾普免疫公司 | 优化的多表位构建体及其应用 |
CN101948811A (zh) * | 2010-08-18 | 2011-01-19 | 中国农业科学院兰州兽医研究所 | 用反向遗传操作拓展口蹄疫疫苗株抗原谱及疫苗制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102372766A (zh) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103172749B (zh) | 一种非洲猪瘟蛋白工程疫苗的制备 | |
CN100354414C (zh) | 一种伪狂犬病gEˉ/gIˉ基因缺失毒株、含有该毒株的灭活疫苗及应用 | |
CN106344917A (zh) | 猪瘟粘膜免疫活疫苗组合物及该疫苗的制备方法 | |
CN105112349B (zh) | 一种羊种布鲁氏菌分子标记疫苗株及其应用 | |
CN102274496B (zh) | 一种O/Asia I型口蹄疫病毒两价基因工程多肽疫苗及制备方法和用途 | |
CN102372766B (zh) | 一种o型口蹄疫多表位疫苗 | |
CN102010876A (zh) | 重组枯草芽孢杆菌ev71-vp1表达载体及其制备方法与应用 | |
CN109021115A (zh) | 一种猪圆环病毒三价亚单位疫苗 | |
Zhang et al. | Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine | |
CN102406929B (zh) | 一种共表达分子佐剂加强型二价口蹄疫蛋白工程疫苗 | |
CN105535957A (zh) | 一种口蹄疫o、a型双价灭活标记疫苗及其制备方法 | |
CN111093698B (zh) | 副粘病毒科表达系统 | |
CN101412984A (zh) | 一种猪链球菌2型三组分亚单位疫苗及应用 | |
CN102847168B (zh) | 一种预防奶牛乳腺炎的核酸疫苗PV-Fn的设计及其构建 | |
CN109055320A (zh) | 一株传染性支气管炎病毒分离株及在疫苗制备中的应用 | |
CN111138553B (zh) | 一种融合蛋白及一种弓形虫亚单位疫苗及其疫苗组合物 | |
CN109053896A (zh) | 一种猪圆环病毒二价基因工程疫苗 | |
CN103992408A (zh) | 一种蓝耳病蛋白工程疫苗的制备 | |
CN106916832A (zh) | O型口蹄疫病毒重组核酸、重组疫苗株及其制备方法和应用 | |
CN100381170C (zh) | 一种口蹄疫双价多肽疫苗及其制备方法和用途 | |
CN1477192A (zh) | 表达猪细小病毒vp2基因的重组伪狂犬病毒及疫苗与制备方法 | |
CN107625960B (zh) | 一种通用型猪大肠杆菌病疫苗及其制备方法 | |
CN106039304A (zh) | 一种猪细小病毒、猪流行性腹泻、大肠埃希氏菌三联疫苗 | |
CN102380095A (zh) | 一种口蹄疫三价多肽疫苗及制备方法和用途 | |
CN102847167B (zh) | 一种预防奶牛乳腺炎的改进型增效核酸疫苗的构建 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: QINGDAO HONGQIAO MINGQIN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: QINGDAO BIOMADE TECHNOLOGY CO., LTD. Effective date: 20130507 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130507 Address after: 266061 Shandong City, Laoshan Province, Zhuzhou Road, No. 153, high-level personnel entrepreneurship center, building, room 1, unit B702 Applicant after: Qingdao Hongqiao Mingqin Biological Technology Co., Ltd. Address before: 266061 Shandong City, Laoshan Province, Zhuzhou Road, No. 153, high-level personnel entrepreneurship center, building, room 1, unit B702 Applicant before: Qingdao Baomaide Biological Medical Technology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU PUTAI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: QINGDAO HONGQIAO MINGQIN BIOTECHNOLOGY CO., LTD. Effective date: 20141115 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266061 QINGDAO, SHANDONG PROVINCE TO: 511356 GUANGZHOU, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141115 Address after: 511356, 202, building 35, West Garden Road, Guangzhou economic and Technological Development Zone, Guangdong, Guangzhou Patentee after: GUANGZHOU PUTAI BIOTECHNOLOGY CO., LTD. Address before: 266061 Shandong City, Laoshan Province, Zhuzhou Road, No. 153, high-level personnel entrepreneurship center, building, room 1, unit B702 Patentee before: Qingdao Hongqiao Mingqin Biological Technology Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170713 Address after: 266061, No. 3, building 185, 903 Shenzhen Road, Laoshan District, Shandong, Qingdao Patentee after: QINGDAO MINGQIN BIOLOGICAL TECHNOLOGY CO., LTD. Address before: 511356, 202, building 35, West Garden Road, Guangzhou economic and Technological Development Zone, Guangdong, Guangzhou Patentee before: GUANGZHOU PUTAI BIOTECHNOLOGY CO., LTD. |
|
TR01 | Transfer of patent right |